Molecular Formula | C18H18N4O3S2 |
Molar Mass | 402.49 |
Density | 1.396±0.06 g/cm3(Predicted) |
Boling Point | 639.4±65.0 °C(Predicted) |
pKa | 9.31±0.60(Predicted) |
Storage Condition | 2-8°C(protect from light) |
In vitro study | The mechanism of action was that BAY57-1293 directly inhibited the ATPase activity of the helicase-trigger complex by Virus in a dose-dependent manner. BAY 57-1293 also exhibited potent antiviral activity against acyclovir-resistant HSV mutants. BAY 57-1293 reduces Aβ caused by herpes simplex type 1 in vero cells by Virus and P-tau. |
In vivo study | BAY57-1293 (oral) in mice and rats lethally disseminated herpes pathogenesis model (0.5 mg/kg), mouse herpes zoster-like skin disease spread model (15 mg/kg), and the mouse ocular herpes model showed strong antiviral activity. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.485 ml | 12.423 ml | 24.845 ml |
5 mM | 0.497 ml | 2.485 ml | 4.969 ml |
10 mM | 0.248 ml | 1.242 ml | 2.485 ml |
5 mM | 0.05 ml | 0.248 ml | 0.497 ml |